Autolus Therapeutics plc
AUTL· Nasdaq
AUTLAutolus Therapeutics plc
Source filing unavailable
| Metric | Q3 2019 | Q3 2018 |
|---|---|---|
| Revenue | $297.00K | $307.00K |
| Net Income | -$27.25M | -$12.86M |
| EPS Diluted | -$0.61 | -$0.33 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Autolus Therapeutics plc · CIK 1730463 · Engraved from SEC EDGAR
